The biotech company had kept the drug available at the higher list price in order to give payers and pharmacy benefit managers time to adjust contracts and minimize supply chain disruptions.
The decision was a loss for Amgen, which had claimed that Sanofi and Regeneron's drug Praluent infringed on its patents for the drug Repatha.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
An analyst wrote that while the data are positive, the bigger question is how the drug will be priced, based on another drug already on the market for the same disease, HoFH, which affects about 1,300 people in the U.S.
Equity research analysts wrote in a note Thursday that the move could have a beneficial read-across to another drug that has the same target as Repatha.